[Is there an advantage to neo- or adjuvant chemotherapy in pancreatic cancer?].
In view of the lack of representative clinical studies indication and potential value of neo-/adjuvant chemotherapy of pancreatic cancer has still to be discussed on the basis of palliative treatment results, prognostic and pathohistological data, theoretical considerations and experimental data. A critical analysis, however, indicates that the widespread therapeutical nihilism at least with regard to adjuvant trials should be obsolete today. On the contrary, adjuvant chemotherapeutic trials should be recommended, alone or in combination with radiation or immunotherapy.
Klapdor
R
R
I. Med. Universitätsklinik, Hamburg.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D006801:Humans; D007167:Immunotherapy; D009367:Neoplasm Staging; D010166:Palliative Care; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D015996:Survival Rate
Ist eine neo- oder adjuvante Chemotherapie beim Pankreaskarzinom sinnvoll?